Valiant Laboratories (NSE:VALIANTLAB) Debt-to-Revenue : 0.00 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Valiant Laboratories Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Valiant Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Valiant Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil. Valiant Laboratories's annualized Revenue for the quarter that ended in Dec. 2024 was ₹1,409 Mil. Valiant Laboratories's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.00.

Valiant Laboratories Debt-to-Revenue Historical Data

The historical data trend for Valiant Laboratories's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valiant Laboratories Debt-to-Revenue Chart

Valiant Laboratories Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Debt-to-Revenue

0.21

0.18

0.42

Valiant Laboratories Quarterly Data
	Mar21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial							-	0.63	-	1.35	-

Competitive Comparison of Valiant Laboratories's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valiant Laboratories's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Valiant Laboratories's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Valiant Laboratories Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Valiant Laboratories's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(16.185	+	750.899)	/	1820.572
	=	0.42

Valiant Laboratories's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	1409.32
	=	0.00

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.

Valiant Laboratories Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Valiant Laboratories's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Valiant Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Valiant Laboratories Ltd (NSE:VALIANTLAB) » Definitions » Debt-to-Revenue

Traded in Other Exchanges

543998:India

Address

Mulund Goregaon Link Road, 104, Udyog Kshetra, Mulund, MH, IND, 400080

Website

https://www.valiantlabs.in

Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.

Valiant Laboratories Headlines

No Headlines